A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet ...

At 48 weeks, 1% of participants in both groups had an HIV-1 RNA level of 50 copies per milliliter or higher, meeting the prespecified noninferiority margin of 4%. Rates of viral suppression below 50 ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, ...

Phase 3 trial results show BIC/LEN is noninferior to BIC/FTC/TAF for maintaining virologic suppression in adults with HIV.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...

Here are three things to know. 1. Trogarzo is an antiretroviral medication for adult patients with HIV who do not respond to other HIV therapies on the market. 2. Clinicians administer the intravenous ...

Sunlenca, a new HIV drug for patients with limited available treatment options, was approved Dec. 22 by the FDA. The new drug is an option for adults with HIV who cannot tolerate, are resistant to or ...

The Philadelphia HIV Resource Finder allows Philadelphians to search for treatment and prevention resources throughout the city.

Share on Pinterest The Trump administration’s plan to cut funding for HIV vaccine research comes at a time when the field is making progress. Victor Torres/Stocksy United The Trump administration ...